ImmuneID’s $50 Million Series A Financing

Gunderson Dettmer Stough Villeneuve Franklin & Hachigian, LLP advised ImmuneID on the deal.

ImmuneID, Inc., a precision immunology company employing a proprietary platform to identify and therapeutically target antibody interactions that drive immune diseases, announced that it has raised $50 million in Series A financing. This Series A financing brings the total amount raised by ImmuneID since its December 2020 launch to over $70 million. Proceeds from the financing will be used to advance the development of therapeutic candidates to treat autoimmune diseases, severe allergies, cancer and infectious diseases.

This Series A round was led by new investor Alta Partners and included new investors Alexandria Venture Investments, Redwood Capital Investments, Section 32 and Tekla Capital Management. All existing investors participated in the financing, including Arch Venture Partners, Longwood Fund, Pitango HealthTech, In-Q-Tel, Xfund and others. This Series A financing follows a $22 million seed financing round that was led by founding investor Longwood Fund.

ImmuneID is a precision immunology company using its proprietary platform to simultaneously identify and therapeutically target millions of antibody interactions that drive immune diseases.

The Gunderson deal team was led by Tim Ehrlich (Picture) and included Georgios Pothoulakis and Jenna Mason.

Involved fees earner: Timothy Ehrlich – Gunderson Dettmer Stough Villeneuve Franklin & Hachigian; Jenna Mason – Gunderson Dettmer Stough Villeneuve Franklin & Hachigian; George Pothoulakis – Gunderson Dettmer Stough Villeneuve Franklin & Hachigian;

Law Firms: Gunderson Dettmer Stough Villeneuve Franklin & Hachigian;

Clients: ImmuneID, Inc.;

Author: Martina Bellini